Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994298032> ?p ?o ?g. }
- W2994298032 endingPage "368" @default.
- W2994298032 startingPage "349" @default.
- W2994298032 abstract "Currently, there are only three FDA-approved drugs that inhibit human immunodeficiency virus (HIV) entry-fusion into host cells. The situation is even worse for enterovirus EV71 infection for which no antiviral therapies are available. We describe here the discovery of potent entry dual inhibitors of HIV and EV71. These compounds contain in their structure three or four tryptophan (Trp) residues linked to a central scaffold. Critical for anti-HIV/EV71 activity is the presence of extra phenyl rings, bearing one or two carboxylates, at the C2 position of the indole ring of each Trp residue. The most potent derivatives, 22 and 30, inhibit early steps of the replicative cycles of HIV-1 and EV-A71 by interacting with their respective viral surfaces (glycoprotein gp120 of HIV and the fivefold axis of the EV-A71 capsid). The high potency, low toxicity, facile chemical synthesis, and great opportunities for chemical optimization make them useful prototypes for future medicinal chemistry studies." @default.
- W2994298032 created "2019-12-13" @default.
- W2994298032 creator A5012314222 @default.
- W2994298032 creator A5015656431 @default.
- W2994298032 creator A5023796496 @default.
- W2994298032 creator A5029939214 @default.
- W2994298032 creator A5030388070 @default.
- W2994298032 creator A5044261377 @default.
- W2994298032 creator A5046330013 @default.
- W2994298032 creator A5048905988 @default.
- W2994298032 creator A5061183502 @default.
- W2994298032 creator A5064479176 @default.
- W2994298032 creator A5065410963 @default.
- W2994298032 creator A5066094878 @default.
- W2994298032 creator A5072256301 @default.
- W2994298032 creator A5074400687 @default.
- W2994298032 creator A5076677420 @default.
- W2994298032 creator A5089010495 @default.
- W2994298032 date "2019-12-06" @default.
- W2994298032 modified "2023-10-14" @default.
- W2994298032 title "Scaffold Simplification Strategy Leads to a Novel Generation of Dual Human Immunodeficiency Virus and Enterovirus-A71 Entry Inhibitors" @default.
- W2994298032 cites W1826915765 @default.
- W2994298032 cites W1964245683 @default.
- W2994298032 cites W1978042026 @default.
- W2994298032 cites W1981636515 @default.
- W2994298032 cites W1982295411 @default.
- W2994298032 cites W1983384565 @default.
- W2994298032 cites W1983484396 @default.
- W2994298032 cites W1985667653 @default.
- W2994298032 cites W2003071165 @default.
- W2994298032 cites W2014189480 @default.
- W2994298032 cites W2020419388 @default.
- W2994298032 cites W2020933095 @default.
- W2994298032 cites W2024062560 @default.
- W2994298032 cites W2024643457 @default.
- W2994298032 cites W2029442766 @default.
- W2994298032 cites W2029582401 @default.
- W2994298032 cites W2031991206 @default.
- W2994298032 cites W2038078673 @default.
- W2994298032 cites W2060640897 @default.
- W2994298032 cites W2061572237 @default.
- W2994298032 cites W2063825413 @default.
- W2994298032 cites W2067786897 @default.
- W2994298032 cites W2075224131 @default.
- W2994298032 cites W2084100238 @default.
- W2994298032 cites W2092279499 @default.
- W2994298032 cites W2095372673 @default.
- W2994298032 cites W2098605123 @default.
- W2994298032 cites W2103213404 @default.
- W2994298032 cites W2105668062 @default.
- W2994298032 cites W2112867551 @default.
- W2994298032 cites W2116500570 @default.
- W2994298032 cites W2117528681 @default.
- W2994298032 cites W2118586318 @default.
- W2994298032 cites W2124026197 @default.
- W2994298032 cites W2130038789 @default.
- W2994298032 cites W2132629607 @default.
- W2994298032 cites W2153545807 @default.
- W2994298032 cites W2154714625 @default.
- W2994298032 cites W2163932237 @default.
- W2994298032 cites W2189679191 @default.
- W2994298032 cites W2193815524 @default.
- W2994298032 cites W2242531545 @default.
- W2994298032 cites W2299902143 @default.
- W2994298032 cites W2320258156 @default.
- W2994298032 cites W2320479585 @default.
- W2994298032 cites W2323825137 @default.
- W2994298032 cites W2327022058 @default.
- W2994298032 cites W2337272231 @default.
- W2994298032 cites W2404280981 @default.
- W2994298032 cites W2410066853 @default.
- W2994298032 cites W2488378867 @default.
- W2994298032 cites W2525073833 @default.
- W2994298032 cites W2567180226 @default.
- W2994298032 cites W2573461614 @default.
- W2994298032 cites W2593511418 @default.
- W2994298032 cites W2605477414 @default.
- W2994298032 cites W2789285266 @default.
- W2994298032 cites W2796452931 @default.
- W2994298032 cites W2803001373 @default.
- W2994298032 cites W2885198426 @default.
- W2994298032 cites W2899714098 @default.
- W2994298032 cites W2943495936 @default.
- W2994298032 cites W2949248222 @default.
- W2994298032 cites W2950967305 @default.
- W2994298032 cites W4244230207 @default.
- W2994298032 cites W50373758 @default.
- W2994298032 doi "https://doi.org/10.1021/acs.jmedchem.9b01737" @default.
- W2994298032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31809045" @default.
- W2994298032 hasPublicationYear "2019" @default.
- W2994298032 type Work @default.
- W2994298032 sameAs 2994298032 @default.
- W2994298032 citedByCount "18" @default.
- W2994298032 countsByYear W29942980322020 @default.
- W2994298032 countsByYear W29942980322021 @default.
- W2994298032 countsByYear W29942980322022 @default.
- W2994298032 countsByYear W29942980322023 @default.
- W2994298032 crossrefType "journal-article" @default.